Why Is Sarepta Therapeutics Stock Surging After The Bell? - Sarepta Therapeutics (NASDAQ:SRPT)

Duchenne Gene Therapy Will Undergo Changes After Patient Deaths

(MedPage Today) -- At the FDA's request, delandistrogene moxeparvovec (Elevidys), the only approved gene therapy for Duchenne muscular dystrophy, will carry a black box warning for acute liver injury and acute liver failure, drugmaker Sarepta Therapeutics...

Sarepta Slashes Staff, Maps Path Forward for Gene Therapy and Narrower Pipeline

Sarepta’s Elevidys will remain on the market with a black box warning. But this gene therapy for Duchenne muscular dystrophy still faces commercial headwinds and analysts say the company has work to do to win over patients and investors. The post Sarepta Slashes Staff, Maps Path Forward for Gene Therapy and Narrower Pipeline appeared first on MedCity News.

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move

The announcement follows the deaths of two teenagers that forced restrictions on use of the company's gene therapy for Duchenne muscular dystrophy.

Sarepta Slashes Workforce After Patient Deaths on Gene Therapy

Sarepta Therapeutics Inc. is cutting more than one-third of its workforce and will add a black box warning label to its gene therapy for a fatal muscle disorder after two patient deaths raised doubts about the future of the company.

Why Is Sarepta Therapeutics Stock Surging After The Bell? - Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics shares are soaring in Wednesday's after-hours session after the company announced a strategic restructuring and cost-cutting measures.

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.